Literature DB >> 7526890

Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells.

C Caux1, C Massacrier, B Vanbervliet, C Barthelemy, Y J Liu, J Banchereau.   

Abstract

Human dendritic cells (DC) generated from CD34+ hematopoietic progenitors cultured in the presence of granulocyte macrophage colony stimulating factor (GM-CSF) and tumor necrosis factor (TNF)-alpha are related to Langerhans cells (DLC) and have been shown to induce a strong proliferation of allogeneic CD4+ T cells. The present study shows that recombinant human IL-10 (h-IL-10) inhibits the primary and secondary proliferative responses of both CD4+ and CD8+ T cells induced by allogeneic CD1a+ DLC. The alloreaction induced by DLC generated after 5-18 days of culture of CD34+ HPC was equally inhibited by h-IL-10, thus indicating that DLC were sensitive to h-IL-10 at all stages of differentiation. This is further indicated by the h-IL-10-induced inhibition of the T cell alloreaction mediated by interdigitating DC freshly isolated from tonsils. h-IL-10 specifically acted on DLC as it did not affect the proliferation induced by Epstein-Barr virus lymphoblastoid cell lines (EBV-LCL) nor that induced by immobilized anti-CD3. The inhibitory effect of h-IL-10 was not due to the production of suppressive factors by the DLC, as the addition of DLC and IL-10 did not inhibit EBV-LCL-induced T cell proliferation. Rather, the inhibition of cytokine production (IL-2, GM-CSF, TNF, IFN-gamma) observed after 24 h of co-culture may explain the inhibition of T cell DNA synthesis detected 3 days later. The h-IL-10-induced inhibition of human DC mediated alloreaction advocates considering the use of h-IL-10 in the prevention of transplant rejection and graft versus host disease, phenomena initiated by DC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526890     DOI: 10.1093/intimm/6.8.1177

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  34 in total

1.  Human major group rhinoviruses downmodulate the accessory function of monocytes by inducing IL-10.

Authors:  J Stöckl; H Vetr; O Majdic; G Zlabinger; E Kuechler; W Knapp
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  Immunoregulation of dendritic cells.

Authors:  Mark A Wallet; Pradip Sen; Roland Tisch
Journal:  Clin Med Res       Date:  2005-08

3.  Induction of FoxP3+CD4+CD25+ regulatory T cells by a bone marrow population distinct from plasmacytoid-DC.

Authors:  Kendra N Taylor; Monika Laszkowska; Evan Cohick; Yolonda L Colson
Journal:  Cell Immunol       Date:  2008-05-23       Impact factor: 4.868

Review 4.  Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Authors:  F Salazar-Onfray
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 5.  Antigen-presenting cells in rheumatoid arthritis.

Authors:  R Thomas
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Adoptive transfer of fibrocytes enhances splenic T-cell numbers and survival in septic peritonitis.

Authors:  Jean A Nemzek; Christopher Fry; Bethany B Moore
Journal:  Shock       Date:  2013-08       Impact factor: 3.454

Review 7.  Dendritic cells and tumor microenvironment: a dangerous liaison.

Authors:  Ingo Fricke; Dmitry I Gabrilovich
Journal:  Immunol Invest       Date:  2006       Impact factor: 3.657

8.  Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.

Authors:  Gianni Gerlini; Adrian Tun-Kyi; Christa Dudli; Günter Burg; Nicola Pimpinelli; Frank O Nestle
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Differential responses of cord and adult blood-derived dendritic cells to dying cells.

Authors:  On Hang Wong; Fang-Ping Huang; Alan K S Chiang
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

10.  CD40-activated human naive surface IgD+ B cells produce IgG2 in response to activated T-cell supernatant.

Authors:  C Servet-Delprat; J M Bridon; D Blanchard; J Banchereau; F Brière
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.